地西他滨联合CAG方案治疗骨髓异常综合征临床研究  

Clinical Study on the Treatment of Myelodysplastic Syndrome With the Combination of CAG and Decitabine

作　　者：高国荣[1] 

机构地区：[1]山西医科大学,太原030001

出　　处：《中国卫生标准管理》2016年第2期83-84,共2页China Health Standard Management

摘　　要：目的研究地西他滨联合CAG（阿克拉霉素、阿糖胞苷及粒细胞刺激因子）方案治疗骨髓异常综合征临床效果。方法选择我院2013年4月1日-2015年10月31日收治的骨髓异常综合征患者42例作为研究对象,将患者分为两组,观察组21例和对照组21例,观察组患者应用地西他滨联合CAG方案进行治疗,对照组患者应用CAG方案进行治疗,比较两组的治疗效果。结果观察组不良反应发生率比对照组低,差异有统计学意义（P〈0.05）;观察组治疗有效率比对照组高,差异有统计学意义（P〈0.05）。结论地西他滨联合CAG方案治疗骨髓异常综合征临床效果较好。Objective To study the treatment of Myelodysplastic Syndrome with the combination of Decitabine and CAG（aclarubicin,cytarabine and Granulocyte Colony-Stimulating Factor）. Methods Selected 42 patients with myelodysplastic syndrome treated from April 1st,2013 to October 31 st,2015,as the research object,and divided the patients into two groups. Observation group 21 cases and the control group 21 cases,observation group of patients with application of Decitabine and CAG,patients in the control group used the CAG solution for treatment,then compared two groups of treatment effect. Results The effective rate of the observation group was lower than the control group,the difference was significant（P〈0.05）. The incidence of adverse reactions of the observation group was higher than the control group,the difference was significant（P〈0.05）. Conclusion The efficacy of decitabine combined with CAG in the treatment of myelodysplastic syndrome is significantly.

关 键 词：地西他滨 CAG 骨髓异常综合征 

分 类 号：R551.3[医药卫生—血液循环系统疾病]